An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

<strong>Objectives</strong> To determine whether the introduction of the capsular group B meningococcal vaccine (4CMenB) in the United Kingdom has increased presentations of infants to Emergency Departments with Adverse Events Following Immunisation (AEFI) <strong>Participants, des...

Bibliografski detalji
Glavni autori:	Nainani, V, Galal, U, Buttery, J, Snape, M
Format:	Journal article
Izdano:	BMJ Publishing Group 2017

Slični predmeti

Meningococcal meningitis presenting postinfant group B meningococcal immunisation
od: So, N, i dr.
Izdano: (2018)

Genomic surveillance and meningococcal group B vaccine coverage estimates after introduction of the vaccine into the national immunisation programme in the UK
od: Rodrigues, C, i dr.
Izdano: (2017)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
od: Snape, MD, i dr.
Izdano: (2006)

Post‐vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation
od: Yonatan Moges Mesfin, i dr.
Izdano: (2021-04-01)

Emerging clinical experience with vaccines against group B meningococcal disease
od: Wilkins, A, i dr.
Izdano: (2017)

MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS
od: Maheshi, R, i dr.
Izdano: (2010)

Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review
od: George Kassianos, i dr.
Izdano: (2023-07-01)

Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey
od: Voysey, M, i dr.
Izdano: (2015)

Meningococcal polysaccharide-protein conjugate vaccines.
od: Snape, MD, i dr.
Izdano: (2005)

Seroprevalence of meningococcal serogroup C bactericidal antibodies in the Portuguese population, a decade after vaccine introduction in the National Immunisation Programme.
od: Paulo Gonçalves, i dr.
Izdano: (2021-01-01)

Correction to: Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review
od: George Kassianos, i dr.
Izdano: (2023-10-01)

Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana
od: Eunice Okyere, i dr.
Izdano: (2023-06-01)

Quantitative Approaches for Causality Assessment of Adverse Events Following Immunisation for COVID-19 Vaccines
od: Shyh Poh Teo
Izdano: (2021-06-01)

The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada
od: Gaston De Serres, i dr.
Izdano: (2022-01-01)

Will booster doses be required for serogroup B meningococcal vaccine?
od: McQuaid, F, i dr.
Izdano: (2014)

Immunisation of adolescents in the UK.
od: Kale, A, i dr.
Izdano: (2011)

Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands
od: Josefien Cornelie Minthe Bousema, i dr.
Izdano: (2015-11-01)

Immunisation of the immunocompromised child
od: Pinto, M, i dr.
Izdano: (2016)

Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study
od: Vinita Shukla, i dr.
Izdano: (2023-03-01)

Frequency of Adverse Events Following Q Fever Immunisation in Young Adults
od: Emily Sellens, i dr.
Izdano: (2018-12-01)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
od: O'Connor, D, i dr.
Izdano: (2020)

IJCM_273A: Severe adverse events following Covid 19 vaccination immunisation in India: Retrospective Study.
od: Sruthikrishna P, i dr.
Izdano: (2024-04-01)

The Prevalence of Invasive Bacterial Infection in Febrile Infants Presenting to Hospital Following Meningococcal B Immunisation: A Case Series
od: Holly Drummond, i dr.
Izdano: (2025-02-01)

Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
od: Snape, MD, i dr.
Izdano: (2005)

Active surveillance study of adverse events following immunisation of children in the Czech Republic
od: Jana Danova, i dr.
Izdano: (2017-02-01)

Meningococcal vaccines: past, present, and future perspectives
od: Seyed Davar Siadat and Dariush Norouzian
Izdano: (2007-10-01)

The next chapter for group B meningococcal vaccines
od: Wang, N, i dr.
Izdano: (2017)

Group B meningococcal vaccine science and policy
od: Drysdale, SB, i dr.
Izdano: (2015)

Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations
od: María Fernández-Prada, i dr.
Izdano: (2018-09-01)

Implementation of data triangulation and dashboard development for COVID-19 vaccine adverse event following immunisation (AEFI) data in Nigeria
od: Omotayo Bolu, i dr.
Izdano: (2023-01-01)

Association of Adverse Events Following Immunisation with COVID-19 Vaccine and Lifestyle of Individuals: A Cross-sectional Analytical Survey
od: Poojita Santosh Rao, i dr.
Izdano: (2023-03-01)

The challenge of post-implementation surveillance for novel meningococcal vaccines.
od: Snape, MD, i dr.
Izdano: (2012)

Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014–19
od: Pasquale Stefanizzi, i dr.
Izdano: (2022-01-01)

A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
od: Riddell, A, i dr.
Izdano: (2007)

A randomised study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide - CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase
od: Riddell, A, i dr.
Izdano: (2007)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
od: Daniel O’Connor, i dr.
Izdano: (2020-11-01)

Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
od: Márcia de Cantuária Tauil, i dr.
Izdano: (2014-07-01)

Knowledge on cervical cancer, human papilloma virus and vaccine, and attitudes towards immunisation following the introduction of vaccine to the National Immunisation Programme, Sri Lanka
od: K. Gunasekera, i dr.
Izdano: (2022-06-01)

Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following immunisation with COVID-19 vaccines: a 15 months update
od: Ciro Manzo, i dr.
Izdano: (2023-10-01)

Vaccine Adverse Event Mining of Twitter Conversations: 2-Phase Classification Study
od: Sedigheh Khademi Habibabadi, i dr.
Izdano: (2022-06-01)